Micromet to Present at Three Upcoming Investor Conferences

BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., Micromet's President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences:

Jefferies 2010 Global Life Sciences Conference

Wednesday, June 9, at 2 PM ET

Grand Hyatt, New York City

9th Annual Needham Healthcare Conference

Thursday, June 10 at 8:40 AM ET

New York Palace Hotel, New York City

31st Annual Goldman Sachs Global Healthcare Conference

Wednesday, June 16 at 11 AM ET

Century Plaza Hyatt Regency, Los Angeles

The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com.  A replay of the webcasts will also be available on the Company's website.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

SOURCE Micromet, Inc.